Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

155.50 +0.83 (+0.54%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

February 14, 2023

From Sentia Medical Sciences, Inc.

Via GlobeNewswire

Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets ↗

February 06, 2023

Neurocrine also topped fourth-quarter revenue expectations on Monday.

Via Investor's Business Daily

Five Best And Worst Performing Healthcare Stocks In January 2023 ↗

February 05, 2023

After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...

Via Talk Markets

Neurocrine Biosciences Earnings Preview ↗

February 03, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗

February 03, 2023

Via Benzinga

Earnings Scheduled For February 6, 2023 ↗

February 06, 2023

Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.

Via Benzinga

Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing' ↗

February 03, 2023

Via Benzinga

Why Voyager Therapeutics Stock Is Sinking This Week ↗

January 20, 2023

Investors are taking profits on this red-hot stock this week.

Via The Motley Fool

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

January 25, 2023

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

Via MarketBeat

7 A-Rated Stocks to Buy for Less Than $25 ↗

January 24, 2023

These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.

Via InvestorPlace

Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review ↗

January 13, 2023

Sharp Tesla price cuts and some notable earnings were in focus.

Via Investor's Business Daily

Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal ↗

January 09, 2023

Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.

Via InvestorPlace

Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies ↗

January 09, 2023

Via Benzinga

Have A Look At William Blair's Top Biotech Picks For 2023 ↗

December 25, 2022

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

Via Benzinga

Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally ↗

December 17, 2022

UnitedHealth is among medical stocks holding key support.

Via Investor's Business Daily

Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth ↗

December 07, 2022

Via Benzinga

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

December 01, 2022

During Thursday's session, 108 stocks hit new 52-week highs.

Via Benzinga

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Heska To $165? Plus BTIG Cuts PT On This Stock By 67% ↗

November 14, 2022

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at...

Via Benzinga

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

November 11, 2022

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

Via MarketBeat

Looking Into Neurocrine Biosciences's Return On Capital Employed ↗

November 09, 2022

According to Benzinga Pro, during Q3, Neurocrine Biosciences (NASDAQ:NBIX) earned $68.50 million, a 505.33% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $387.90...

Via Benzinga

Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review ↗

November 04, 2022

A mixed jobs report and heavy earnings swung stocks.

Via Investor's Business Daily

Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat ↗

November 01, 2022

The company raised its guidance for Ingrezza sales in 2022.

Via Investor's Business Daily

Neurocrine Biosciences: Q3 Earnings Insights ↗

November 01, 2022

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗

October 11, 2022

Upgrades

Via Benzinga

Earnings Scheduled For November 1, 2022 ↗

November 01, 2022

Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.

Via Benzinga

3 Top Biotech Stocks Defying the Bear Market ↗

October 11, 2022

Bear market, shmear market. These biotech stocks are soaring despite the market downturn.

Via The Motley Fool

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

4 Analysts Have This to Say About Neurocrine Biosciences ↗

September 26, 2022

Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.